HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: An analysis of archived Kenyan blood samples

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Lihana, Raphael W ^a   Khamadi, Samoel A ^a   Lwembe, Raphael M ^a   Kinyua, Joyceline G ^a   Muriuki, Joseph K ^a   Lagat, Nancy J ^a   Okoth, Fredrick A ^a   Makokha, Ernest P ^a   Songok, Elijah M ^a,b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GAG PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DNA SEQUENCE; DRUG USE; ENVELOPE GENE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; STRUCTURAL GENE; VIROGENESIS; VIRUS RECOMBINATION; VIRUS RESISTANCE; ADOLESCENT; BLOOD; CLASSIFICATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE ANALYSIS; VIRAL TROPISM; VIROLOGY;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; RECEPTORS, CCR5; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; VIRAL TROPISM; YOUNG ADULT;

EID: 74549157681     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-215     Document Type: Article

References (33)

1. Piot P, Bartos M. The epidemiology of HIV and AIDS. AIDS in Africa 2002, 200-17. New York. Kluwer Academic/Plenum Publishers, Essex M, Mboup S, Kanki PJ, Marlink PJ, Tlou SD, 2.
2. Joint United Nations program on HIV/AIDS (UNAIDS). , http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_ Global_report.asp
3. Renjifo B, Essex M. HIV-1 subtypes and recombinants. AIDS in Africa 2002, 138-57. New York. Kluwer Academic/Plenum Publishers, Essex M, Mboup S, Kanki PJ, Marlink PJ, Tlou SD, 2.
4. Simon F, Mauclère P, Roques P, Loussert-Ajaka I, Müller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barré-Sinoussi F, Brun-Vézinet F. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Medicine 1998, 4:1032-37. 10.1038/2017, 9734396.
5. Thomson MM, Perez Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002, 2:461-471. 10.1016/S1473-3099(02)00343-2, 12150845.
6. Peeters M, Sharp PM. Genetic diversity of HIV-1: the moving target. AIDS 2000, 14:S129-S140. 10.1097/00002030-200012010-00001, 11086856.
7. The Circulating Recombinant Forms (CRFs). , http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html
8. Janssens W, Heyntrickx L, FransenK Temmerman M, Leonaers A, Ivens T, Motte J, Piot P, Groen G. Genetic Variability of HIV type 1 in Kenya. AIDS Res Hum Retroviruses 1994, 10:1577-1579. 10.1089/aid.1994.10.1577, 7888213.
9. Heyndrickx L, Janssens W, Zekeng L, Musonda R, Anagonou S, Auwera G, Coppens S, Vereecken K, De Witte K, Van Rampelbergh R, Kahindo M, Morison L, McCutchan FE, Carr JK, Albert J, Essex M, Goudsmit J, Asjö B, Salminen M, Buvé A, Groen G. Simplified strategy for detection of recombinat human immunodeficiency virus type 1 group M isolates by gag/env Heteroduplex Mobility Assay. J Virol 2000, 74:363-370. 10.1128/JVI.74.1.363-370.2000, 111547, 10590125.
10. Dowling WE, Kim B, Mason CJ, Wasunna KM, Alam U, Elson L, Birx DL, Robb ML, McCutchan FE, Carr JK. Fourty one near full length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A containing recombinants. AIDS 2002, 16:1809-1820. 10.1097/00002030-200209060-00015, 12218394.
11. Songok EM, Lihana RW, Kiptoo MK, Genga IO, Kibaya R, Odhiambo F, Kobayashi K, Ago Y, Ndembi N, Okoth F, Fujiyama Y, Imanishi J, Ichimura H. Identification of env CRF10 among HIV variants circulating in rural western Kenya. AIDS Res Hum Retroviruses 2003, 19(2):161-165. 10.1089/088922203762688676, 12643281.
12. Carrion G, Hierholzer J, Montano S, Alava A, Perez J, Guevara A, Laguna-Torres V, Mosquera C, Russell K, Chauca G, Kochel T, Birx DL, Sanchez JL, Carr JK. Circulating Recombinant Form CRF02-AG in South America. AIDS Res Hum Retroviruses 2003, 19(4):329-332. 10.1089/088922203764969537, 12816083.
13. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Muñoz JL. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255(5048):1134-7. 10.1126/science.1546316, 1546316.
14. Regoes RR, Bonhoeffer S. The HIV co-receptor switch: a population dynamical perspective. Trends Microbiol 2005, 13(6):269-77. 10.1016/j.tim.2005.04.005, 15936659.
15. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002, 185:1244-50. 10.1086/340130, 12001041.
16. Kanki PJ, Hamel DJ, Sankalé JL, Hsieh C, Thior I, Barin F, Woodcock SA, Guèye-diaye A, Zhang E, Montano M, Siby T, Marlink R, NDoye I, Essex ME, MBoup S. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999, 179:68-73. 10.1086/314557, 9841824.
17. Wang Y, Song A, Xu S, Li X, Chong H, Zhao C, Nie J, Zhang C. Impact of HIV-1 genetic diversity in China on the measurement of viral load. J Med Virol 2008, 80(1):1-8. 10.1002/jmv.21048, 18041045.
18. Lwembe R, Ochieng W, Panikulam A, Mongoina CO, Palakudy T, Koizumi Y, Kageyama S, Yamamoto N, Shioda T, Musoke R, Owens M, Songok EM, Okoth FA, Ichimura H. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007, 79(7):865-72. 10.1002/jmv.20912, 17516531.
19. Wainberg MA. Perspectives on antiviral drug development. Antiviral Res 2009, 81(1):1-5. 10.1016/j.antiviral.2008.09.003, 18948140.
20. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003, 51(2):229-40. 10.1093/jac/dkg079, 12562686.
21. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the Drug resistance Mutations in HIV-1. Top HIV Med 2008, 16(5):138-45.
22. de Mendoza C, Rodriguez C, García F, Eiros JM, Ruíz L, Caballero E, Aguilera A, Leiva P, Colomina J, Gutierrez F, del Romero J, Aguero J, Soriano V, . Spanish HIV Seroconverter Study Group Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007, 59(4):698-704. 10.1093/jac/dkm012, 17327295, Spanish HIV Seroconverter Study Group.
23. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, Ryst E, . MOTIVATE 1 and MOTIVATE 2 Study Teams Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359(14):1442-55. 10.1056/NEJMoa0803154, 18832245, MOTIVATE 1 and MOTIVATE 2 Study Teams.
24. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, Ryst E, Mayer H, . A4001029 Study Group A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1. J Infect Dis 2009, 199(11):1638-1647. 10.1086/598965, 19432546, A4001029 Study Group.
25. Saitou N, Neil M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1997, 4:406-425.
26. Page RDM. TREEVIEW: An application to display phylogenetic trees on personal computers. Computer Applications in Biosciences 1996, 12:357-358.
27. Gao F, Vidal N, Li Y, Trask SA, Chen Y, Kostrikis LG, Ho DD, Kim J, Oh MD, Choe K, Salminen M, Robertson DL, Shaw GM, Hahn BH, Peeters M. Evidence of two distinct subtypes within the HIV-1 subtype A radiation. AIDS Res Hum Retroviruses 2001, 8:675-688.
28. Poss M, Gosink J, Thomas E, Kreiss JK, Ndinya Achola J, Mandaliya K, Bwayo J, Overbaugh J. Phylogenetic Evaluation of Kenyan HIV type 1 Isolates. AIDS Res Hum Retroviruses 1997, 13:493-499. 10.1089/aid.1997.13.493, 9100991.
29. National AIDS and STD Control Programme (NASCOP). Kenya Ministry of Health Treatment, care and support. National AIDS and STD Control Programme (NASCOP). Kenya Ministry of Health., http://www.aidskenya.org/Programmes/Treatment--Care-&-Support
30. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44(4):591-5. 10.1086/511035, 17243065.
31. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005, 192(3):466-74. 10.1086/431519, 15995960.
32. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006, 194:926-30. 10.1086/507312, 16960780.
33. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-8. 10.1126/science.1118398, 2408531, 16284180.